<DOC>
	<DOCNO>NCT02631590</DOCNO>
	<brief_summary>The purpose study see experimental drug , call copanlisib effective safe treat adult participant cholangiocarcinoma , use combination gemcitabine cisplatin .</brief_summary>
	<brief_title>Copanlisib ( BAY 80-6946 ) Combination With Gemcitabine Cisplatin Advanced Cholangiocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Must histologically cytologically document carcinoma primary intra extrahepatic biliary system gall bladder clinical and/or radiologic evidence unresectable , locally advanced metastatic disease . Patients ampullary carcinoma eligible . Must receive systemic chemotherapy advance biliary cancer . Patients receive adjuvant chemotherapy plus minus radiation evidence disease recurrence within 6 month completion adjuvant treatment eligible . If patient receive adjuvant treatment disease recurrence 6 month , patient eligible . Eastern Cooperative Oncology Group ( ECOG ) Performance Status Assessment 0 1 . Must radiographic measurable disease . Life expectancy least 12 week ( 3 month ) . For patient receive prior radiation , cryotherapy , radiofrequency ablation , therasphere , ethanol injection , transarterial chemoembolization ( TACE ) photodynamic therapy , follow criterion must meet : 28 day elapse since therapy ; Lesions treat local therapy must present measureable . Adequate bone marrow , liver liver function . Women childbearing potential must negative serum pregnancy test perform within 7 day prior start study drug . Men woman childbearing potential must agree use adequate contraception begin sign Informed Consent Form ( ICF ) least 3 month last dose study drug . Must able swallow retain oral medication . Previous concurrent cancer within 3 year prior treatment start except curatively treated cervical cancer situ , nonmelanoma skin cancer superficial bladder tumor [ Ta ( noninvasive tumor ) , Tis ( carcinoma situ ) T1 ( tumor invades lamina propria ) ] . Congestive heart failure &gt; New York Heart Association ( NYHA ) class 2 . Unstable angina ( angina symptom rest ) , newonset angina ( begin within last 3 month ) . Myocardial infarction le 6 month study enrollment Uncontrolled hypertension ( blood pressure ≥ 150/90 mmHg despite optimal medical management ) . Arterial venous thrombotic embolic event cerebrovascular accident ( include transient ischemic attack ) , deep vein thrombosis pulmonary embolism within 6 month enrollment . Nonhealing wound , ulcer , bone fracture . Active clinically serious infection ( &gt; Common Terminology Criteria Adverse Events ( CTCAE ) grade 2 ) . Known history human immunodeficiency virus ( HIV ) infection . Known active Hepatitis B C. A seizure disorder require medication . Evidence history bleed diathesis . Any hemorrhage bleeding event ≥ CTCAE Grade 3 within 4 week start study enrollment . Substance abuse , medical , psychological social condition may interfere patient 's participation study evaluation study result . Known hypersensitivity test drug , test drug class , excipients formulation . History concurrent condition interstitial lung disease grade severely impaired pulmonary function . Unresolved toxicity high CTCAE grade 1 attributed prior therapy/procedure exclude alopecia . HbA1c &gt; 8.5 % fast plasma glucose &gt; 160 mg/dL screening . Concurrent diagnosis pheochromocytoma . Women pregnant breast feeding . Any illness medical condition unstable could jeopardize safety patient his/her compliance study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>intra-hepatic biliary system</keyword>
	<keyword>extra-hepatic biliary system</keyword>
	<keyword>gall bladder</keyword>
	<keyword>advanced biliary cancer</keyword>
	<keyword>unresectable</keyword>
	<keyword>locally advanced</keyword>
	<keyword>metastatic disease</keyword>
</DOC>